mouse monoclonal anti rrm2 antibody  (Novus Biologicals)

Journal: OncoTargets and therapy

Article Title: Ribonucleotide reductase subunit M2 as a novel target for clear-cell renal cell carcinoma

doi: 10.2147/OTT.S196347

Figure Lengend Snippet: RRM2 is upregulated in ccRCC and predicts poor prognosis. (A) The mRNA level of RRM2 in tissues from 10 cases of ccRCC and the corresponding normal renal tissues was examined using RT-qPCR analysis. ** P <0.01. (B) IHC staining was performed in 90 cases of ccRCC tissues and 30 cases of normal renal tissues. The representative images of RRM2 expression in the cell cytoplasm are shown (×400). The scale bar represents 50 µm. (C) The IHC score of RRM2 in the above samples. ** P <0.01. (D) Survival analysis of RCC patients related to RRM2 expression was analyzed by Kaplan–Meier survival curves. Abbreviations: ccRCC, clear-cell renal cell carcinoma; IHC, immunohistochemistry; RRM2, ribonucleotide reductase subunit M2.

Article Snippet: 16 Briefly, the proteins of the cells on the membrane were incubated with a primary mouse monoclonal antibody against human RRM2 (1:1000 dilution; ab57653; Abcam) at 4 °C overnight.

Techniques: Quantitative RT-PCR, Immunohistochemistry, Expressing

Journal: OncoTargets and therapy

Article Title: Ribonucleotide reductase subunit M2 as a novel target for clear-cell renal cell carcinoma

doi: 10.2147/OTT.S196347

Figure Lengend Snippet: Expression of RRM2 in ccRCC and normal tissues

Article Snippet: 16 Briefly, the proteins of the cells on the membrane were incubated with a primary mouse monoclonal antibody against human RRM2 (1:1000 dilution; ab57653; Abcam) at 4 °C overnight.

Techniques: Expressing

Journal: OncoTargets and therapy

Article Title: Ribonucleotide reductase subunit M2 as a novel target for clear-cell renal cell carcinoma

doi: 10.2147/OTT.S196347

Figure Lengend Snippet: Association of RRM2 expression with clinicopathologic characteristics in ccRCC

Article Snippet: 16 Briefly, the proteins of the cells on the membrane were incubated with a primary mouse monoclonal antibody against human RRM2 (1:1000 dilution; ab57653; Abcam) at 4 °C overnight.

Techniques: Expressing

Journal: OncoTargets and therapy

Article Title: Ribonucleotide reductase subunit M2 as a novel target for clear-cell renal cell carcinoma

doi: 10.2147/OTT.S196347

Figure Lengend Snippet: Univariate and multivariate Cox regression analysis for overall survival in ccRCC

Article Snippet: 16 Briefly, the proteins of the cells on the membrane were incubated with a primary mouse monoclonal antibody against human RRM2 (1:1000 dilution; ab57653; Abcam) at 4 °C overnight.

Techniques: Expressing

Journal: OncoTargets and therapy

Article Title: Ribonucleotide reductase subunit M2 as a novel target for clear-cell renal cell carcinoma

doi: 10.2147/OTT.S196347

Figure Lengend Snippet: Knockdown of RRM2 inhibits the proliferation and induces G0/G1 arrest in RCC cells through attenuation of the dNTP pool. (A) Western blotting showed that knockdown of RRM2 using siRNAs could effectively decrease the protein expression of RRM2 in 786-O and 769-P cells. (B) The proliferation assay showed that the viability of 786-O and 769-P cells was significantly decreased by the knockdown of RRM2. * P <0.05; *** P <0.001. (C) Flow cytometry showed that the knockdown of RRM2 induced G0/G1 arrest in 786-O and 769-P cells. *** P <0.001. (D) LC-MS/MS analysis showed that the knockdown of RRM2 significantly decreased the dNTP pool, individually dATP and dGTP, in 786-O and 769-P cells. *** P <0.001. Abbreviations: NC, negative control; RRM2, ribonucleotide reductase subunit M2.

Article Snippet: 16 Briefly, the proteins of the cells on the membrane were incubated with a primary mouse monoclonal antibody against human RRM2 (1:1000 dilution; ab57653; Abcam) at 4 °C overnight.

Techniques: Knockdown, Western Blot, Expressing, Proliferation Assay, Flow Cytometry, Liquid Chromatography with Mass Spectroscopy, Negative Control

Journal: OncoTargets and therapy

Article Title: Ribonucleotide reductase subunit M2 as a novel target for clear-cell renal cell carcinoma

doi: 10.2147/OTT.S196347

Figure Lengend Snippet: RRM2 inhibitor reduces the viability of RCC cells by inducing the G0/G1 arrest. (A) 786-O and 769-P cells were treated with 0.5, 1, or 2 μM Triapine for 24, 48, and 72 hours respectively. The cell viability was assessed by CCK-8 assay. (B) 786-O and 769-P cells were treated with 0.5, 1, or 2 μM Triapine respectively, for 48 hours. The cell cycle distribution was detected by PI staining and shown in the bar graph as percentages of cells. Error bars represent the mean ± SD of three independent experiments. *** P <0.001. (C) 786-O and 769-P cells were treated with 0.5, 1, or 2 μM Triapine, respectively, for 72 hours. Apoptotic cells were detected by PI/Annexin V dual staining and shown in the bar graph as percentages of cells. Error bars represent mean ± SD of three independent experiments. Abbreviations: n.s., not significant; PI, propidium iodide; RCC, renal cell carcinoma; RRM2, ribonucleotide reductase subunit M2.

Article Snippet: 16 Briefly, the proteins of the cells on the membrane were incubated with a primary mouse monoclonal antibody against human RRM2 (1:1000 dilution; ab57653; Abcam) at 4 °C overnight.

Techniques: CCK-8 Assay, Staining

Journal: Molecular Cell

Article Title: Ribonucleotide Reductase Requires Subunit Switching in Hypoxia to Maintain DNA Replication

doi: 10.1016/j.molcel.2017.03.005

Figure Lengend Snippet: Effects of RRM2B Depletion in Hypoxia (A) Immunoprecipitation of RRM1 followed by immunoblotting for RRM2B and RRM2 in normoxia and <0.1% O 2 (18 hr). (B) dNTP levels in RKO cells treated with non-specific (siCTL) or siRRM2B and exposed to <0.1% O 2 (16 hr). (C) FACS analysis of U2OS cells treated with siCTL or siRRM2B and exposed to normoxia or <0.1% O 2 (3 hr). Cells were pulsed with bromodeoxyuridine (BrdU) (20 μM) 30 min before collection. (D) RPA32 foci in RKO RRM2B+/+ and RKO RRM2B−/− cells after exposure to <0.1% O 2 . (E) 53BP1 foci in RKO RRM2B+/+ and RKO RRM2B−/− cells exposed to normoxia or <0.1% O 2 (6 hr). (F) Representative images of 53BP1 foci in RRM2B-negative RKO cells treated with siRRM2B and exposed to normoxia or <0.1% O 2 (6 hr). Scale bar, 20 μm. (G) Colony survival assay in RKO cells treated with siCTL or siRRM2B and exposed to normoxia or <0.1% O 2 (24 hr). (H) Apoptosis detected morphologically in RKO cells treated with siCTL or siRRM2B and exposed to normoxia or <0.1% O 2 (19 hr). (I) RKO RRM2B+/+ and RKO RRM2B−/− cells were grown as xenografts in mice (n = 4 mice per each group). Where indicated, irradiation (10 Gy) was given when tumors reached ∼100 mm 3 . (J) Representative images of co-localization of cleaved caspase-3 (apoptosis) with PIMO (hypoxic areas) in RKO RRM2B+/+ or RKO RRM2B−/− xenografts. Scale bars, 50 μm. (K and L) Tumors were removed on day 28 post-implantation (from H), and the level of apoptosis was quantified in normoxic areas (PIMO negative) (K) and hypoxic areas (PIMO positive) (L). Images from three different tumors (n = 3) per group were counted. For all panels, n = 3 (biological replicates) unless otherwise stated. Data show mean ± SEM and two-tailed Student’s t test was applied, except in (D), where one-way ANOVA analysis was applied, and (I), where two-way ANOVA analysis was applied. (ns) indicates a non-significant change. See also and .

Article Snippet: Mouse monoclonal anti-RRM2 Clone 1E1 , Bio-Rad , Cat# MCA3434Z.

Techniques: Immunoprecipitation, Western Blot, Clonogenic Cell Survival Assay, Irradiation, Two Tailed Test

Journal: Molecular Cell

Article Title: Ribonucleotide Reductase Requires Subunit Switching in Hypoxia to Maintain DNA Replication

doi: 10.1016/j.molcel.2017.03.005

Figure Lengend Snippet: RRM2B Retains Activity in Hypoxia (A) Product formation (percentage of the maximum, where maximum is the dCDP levels at 30 min in normoxia) for R1/R2B enzyme in normoxia and <0.1% O 2 . (B) dCDP (μM) in <0.1% O 2 for R1/R2B for the times indicated. Activity of R1/R2B enzyme at 37°C at 5 min in <0.1% O 2 was 19.57 nmol/min/mg RRM2B protein. Gray columns indicate the amount of dCDP formed up to 15 min in <0.1% O 2 , and red columns indicate the amount of dCDP formed after 15 min in <0.1% O 2. (C) Product formation (percentage of the maximum, where maximum is the dCDP levels at 30 min in normoxia) for R1/R2 enzyme in normoxia and <0.1% O 2 . (D) dCDP (μM) in <0.1% O 2 for R1/R2 for the times indicated. Activity of R1/R2 enzyme at 37°C at 5 min in <0.1% O 2 was 97.74 nmol/min/mg RRM2 protein. Gray columns indicate the amount of dCDP formed up to 15 min in <0.1% O 2 , and red columns indicate the amount of dCDP formed after 15 min in <0.1% O 2. (E and F) Characterization of the oxygen tunnels (T1–T3) of RRM2B (E) and RRM2 (F). (G and H) EPR spectra of the tyrosyl radical of RRM2B (G) and RRM2 (H) in normoxia and <0.1% O 2 , respectively. (I) Quantification of (G) and (H). Data present electron spins per β subunit. For all panels, n = 3 (biological replicates); for (A) and (C), data represent mean ± SEM and two-way ANOVA was applied; for (B) and (D), data represent mean ± SEM and two-tailed Student’s t test was applied; (ns) indicates non significant change. See also Figure S5 .

Article Snippet: Mouse monoclonal anti-RRM2 Clone 1E1 , Bio-Rad , Cat# MCA3434Z.

Techniques: Activity Assay, Two Tailed Test

Journal: Molecular Cell

Article Title: Ribonucleotide Reductase Requires Subunit Switching in Hypoxia to Maintain DNA Replication

doi: 10.1016/j.molcel.2017.03.005

Figure Lengend Snippet: O 2 Residence Times around the Fe Metallocenter for RRM2B and RRM2 Proteins

Article Snippet: Mouse monoclonal anti-RRM2 Clone 1E1 , Bio-Rad , Cat# MCA3434Z.

Techniques:

Journal: Molecular Cell

Article Title: Ribonucleotide Reductase Requires Subunit Switching in Hypoxia to Maintain DNA Replication

doi: 10.1016/j.molcel.2017.03.005

Figure Lengend Snippet: Critical Roles of K37/K151 and Y164 in RRM2B (A and B) Product formation (percentage of the maximum, where maximum is the dCDP levels at 30 min in normoxia) for K37E/K151E (A) and Y164C (B) in normoxia and <0.1% O 2 . (C) EPR spectra of the tyrosyl radical of Y164C, K37E/K151E, and Q127K (as a negative control) in normoxia and <0.1% O 2 . (D) Quantification of (C). Data present electron spins per β subunit. (E) The RRM2B phenylalanine network around Y164 and phenylalanine conformation in Y164C mutation. Distance plot reveals the effect of Y164C in F95-F197 distance. Color code: WT (black), Y164C (red). (F and G) dATP (F) and dTTP (G) levels in RKO RRM2B−/− cells transfected with CTL, WT, Y164C, or K37E/K151E and exposed to <0.1% O 2 (16 hr). (H) Immunoblot for PARP cleavage in RKO RRM2B−/− cells treated as in (F) and (G) plus Q127K and exposed to <0.1% O 2 (19 hr). (I) Apoptosis detected morphologically in RKO RRM2B−/− cells treated as in (H). (J) Schematic representation of our proposed model. Hypoxia leads to severely compromised activity of RRM2, leading to replication stress. RRM2B is then induced through the DDR pathway to maintain ongoing replication. However, insufficient dNTPs are generated by R1/R2B, and replication stress is unresolved. The importance of RRM2B activity is that while it does not resolve replication stress, it does maintain replication fork integrity and prevents the accumulation of DNA damage and loss of genome stability. For (A), n = 3; for (B), n = 4 (biological replicates) and two-way ANOVA was applied; for (C), n = 2 (biological replicates); for (F)–(I), n = 3 (biological replicates); data represent means ± SEM and two-tailed Student’s t test was applied. See also and .

Article Snippet: Mouse monoclonal anti-RRM2 Clone 1E1 , Bio-Rad , Cat# MCA3434Z.

Techniques: Negative Control, Mutagenesis, Transfection, Western Blot, Activity Assay, Generated, Two Tailed Test

Journal: Molecular Cell

Article Title: Ribonucleotide Reductase Requires Subunit Switching in Hypoxia to Maintain DNA Replication

doi: 10.1016/j.molcel.2017.03.005

Figure Lengend Snippet:

Article Snippet: Mouse monoclonal anti-RRM2 Clone 1E1 , Bio-Rad , Cat# MCA3434Z.

Techniques: Transduction, Recombinant, Protease Inhibitor, SYBR Green Assay, Mutagenesis, Purification, Gel Extraction, Imaging, Sequencing, Negative Control, Real-time Polymerase Chain Reaction, Software, Expressing

Journal: Molecular medicine reports

Article Title: Ribonucleotide reductase M2 subunit expression and prognostic value in nasopharyngeal carcinoma.

doi: 10.3892/mmr.2015.3360

Figure Lengend Snippet: Figure 1. RRM2 expression in cell lines and nasopharyngeal tissues. (A) RRM2 mRNA expression level in the NPC cell lines was higher than that of the NPECs and the two immortalized NPECs. Three independent experi ments were performed. (B) RRM2 expression was higher in the NPC cell lines compared with the NPEC1-Bmi1 cell line. (C) RRM2 mRNA expression levels in 60 NPC specimens and 20 noncancerous nasopharyngeal epithelial tissues were determined using reverse transcription‑quantitative polymerase chain reaction (P﹤0.01). RRM2, ribonucleotide reductase M2 subunit; NPEC, nasopharyngeal epithelial cell lines; NPC, nasopharyngeal carci noma; Gapdh, Glyceraldehyde 3-phosphate dehydrogenase.

Article Snippet: Once the retrieval solution had cooled to room temperature (for 2 h NPC, nasopharyngeal carcinoma; NKUC, non-keratinizing undifferentiated carcinoma; NKDC; non-keratinizing differentiated carcinoma; UICC, international union against cancer; T stage, tumor stage; N stage, regional lymph node stage; WHO, world health organization. to reach approximately 26 ̊C), the sections were incubated either with diluted mouse monoclonal anti-RRM2 antibody (1:200; NBP1-69832; Novus Biologicals, Littleton, CO, USA) or with the negative control (mouse immunoglobulin G; Abcam, Shanghai, China), overnight at 4 ̊C.

Techniques: Expressing, Polymerase Chain Reaction

Journal: Molecular medicine reports

Article Title: Ribonucleotide reductase M2 subunit expression and prognostic value in nasopharyngeal carcinoma.

doi: 10.3892/mmr.2015.3360

Figure Lengend Snippet: Figure 2. Measurement of RRM2 protein expression using immunohistochemistry analysis in nasopharyngeal carcinoma tissues. RRM2 protein expression was primarily localized in the cytoplasm. Representative images of nasopharyngeal carcinoma grading: (A) Negative control, not expressing RRM2 (x400; n=4); (B) weak staining (x400; n=16); (C) moderate staining (x400; n=20); and (D) strong staining (x400; n=16). RRM2, ribonucleotide reductase M2 subunit.

Article Snippet: Once the retrieval solution had cooled to room temperature (for 2 h NPC, nasopharyngeal carcinoma; NKUC, non-keratinizing undifferentiated carcinoma; NKDC; non-keratinizing differentiated carcinoma; UICC, international union against cancer; T stage, tumor stage; N stage, regional lymph node stage; WHO, world health organization. to reach approximately 26 ̊C), the sections were incubated either with diluted mouse monoclonal anti-RRM2 antibody (1:200; NBP1-69832; Novus Biologicals, Littleton, CO, USA) or with the negative control (mouse immunoglobulin G; Abcam, Shanghai, China), overnight at 4 ̊C.

Techniques: Expressing, Immunohistochemistry, Negative Control, Staining

Journal: Molecular medicine reports

Article Title: Ribonucleotide reductase M2 subunit expression and prognostic value in nasopharyngeal carcinoma.

doi: 10.3892/mmr.2015.3360

Figure Lengend Snippet: Figure 3. Correlation between RRM2 expression and NPC patient survival using Kaplan-Meier survival curve and log-rank test analyses. (A) Of 56 patients with NPC, 51.8% had an OS of five years. (B) High RRM2 expression level was significantly correlated with OS (P<0.05) in patients with NPC. (C) A high RRM2 expression level was significantly correlated with OS (P<0.001) in patients with an early stage of NPC (UICC stage Ⅰ-Ⅱ). (D) A high RRM2 expression level was significantly associated with OS (P<0.05) in patients with an advanced stage of NPC (UICC stage Ⅲ-Ⅳ). RRM2, ribonucleotide reductase M2 subunit; NPC, nasopharyngeal carcinoma; OS, Overall survival; Cum, cumulative; UICC, international union against cancer.

Article Snippet: Once the retrieval solution had cooled to room temperature (for 2 h NPC, nasopharyngeal carcinoma; NKUC, non-keratinizing undifferentiated carcinoma; NKDC; non-keratinizing differentiated carcinoma; UICC, international union against cancer; T stage, tumor stage; N stage, regional lymph node stage; WHO, world health organization. to reach approximately 26 ̊C), the sections were incubated either with diluted mouse monoclonal anti-RRM2 antibody (1:200; NBP1-69832; Novus Biologicals, Littleton, CO, USA) or with the negative control (mouse immunoglobulin G; Abcam, Shanghai, China), overnight at 4 ̊C.

Techniques: Expressing

Journal: Molecular medicine reports

Article Title: Ribonucleotide reductase M2 subunit expression and prognostic value in nasopharyngeal carcinoma.

doi: 10.3892/mmr.2015.3360

Figure Lengend Snippet: Figure 4. RRM2 overexpression enhanced NPC cell proliferation, colony formation, migration and invasion capability. All data are expressed as the mean ± stan dard deviation. (A) Overexpression of RRM2 in HNE1 cells at 36 h post-transfection. HNE1 cells were transfected either with the pcDNA3.1-RRM2 vector or the control plasmid pcDNA3.1 vector. RRM2 mRNA levels increased in HNE1-pcDNA3.1-RRM2 cells according to real time quantitative‑polymerase chain reaction. (B) Western blot analysis showed the RRM2 protein level expression in cells overexpressing RRM2 and control cells following transfec tion. (C) Growth curves of the cells overexpressing RRM2 and control cells. Following RRM2 transient transfection, the cells overexpressing RRM2 grew significantly faster than the control cells during days 3-5 (*P<0.05). (D) Colony formation assay of the cells overexpressing RRM2 and control cells. Cells overexpressing RRM2 formed more colonies compared with the control cells (**P<0.01). (E) Wound healing assay of the cells overexpressing RRM2 and con trol cells. Cells overexpressing RRM2 exhibited a greater wound healing response compared with the control cells. (F) Transwell migration assay of the cells overexpressing RRM2 and control cells. The migration capability was higher in the cells overexpressing RRM2 compared with the control cells (**P<0.01). RRM2, ribonucleotide reductase M2 subunit; NPC, nasopharyngeal carcinoma; Gapdh, Glyceraldehyde 3-phosphate dehydrogenase.

Article Snippet: Once the retrieval solution had cooled to room temperature (for 2 h NPC, nasopharyngeal carcinoma; NKUC, non-keratinizing undifferentiated carcinoma; NKDC; non-keratinizing differentiated carcinoma; UICC, international union against cancer; T stage, tumor stage; N stage, regional lymph node stage; WHO, world health organization. to reach approximately 26 ̊C), the sections were incubated either with diluted mouse monoclonal anti-RRM2 antibody (1:200; NBP1-69832; Novus Biologicals, Littleton, CO, USA) or with the negative control (mouse immunoglobulin G; Abcam, Shanghai, China), overnight at 4 ̊C.

Techniques: Over Expression, Migration, Transfection, Plasmid Preparation, Control, Real-time Polymerase Chain Reaction, Western Blot, Expressing, Colony Assay, Wound Healing Assay, Transwell Migration Assay

Journal: Gut and Liver

Article Title: High Expression of Ribonucleotide Reductase Subunit M2 Correlates with Poor Prognosis of Hepatocellular Carcinoma

doi: 10.5009/gnl13392

Figure Lengend Snippet: Immunostaining of ribonucleotide reductase subunit M2 in hepatocellular carcinomas showing low expression (A) or high expression (B) (horseradish peroxidase stain, ×200).

Article Snippet: Sections were incubated with mouse monoclonal antibody to RRM2 (clone 1E1, 1:800; Abcam Corp., Cambridge, MA, USA) for 30 minutes at room temperature.

Techniques: Immunostaining, Expressing, Staining

Journal: Gut and Liver

Article Title: High Expression of Ribonucleotide Reductase Subunit M2 Correlates with Poor Prognosis of Hepatocellular Carcinoma

doi: 10.5009/gnl13392

Figure Lengend Snippet: Ribonucleotide reductase subunit M2 immunoreactivity in hepatocellular carcinomas (right lower part) was similar to that in normal hepatocytes (left upper part) (horseradish peroxidase stain, ×100).

Article Snippet: Sections were incubated with mouse monoclonal antibody to RRM2 (clone 1E1, 1:800; Abcam Corp., Cambridge, MA, USA) for 30 minutes at room temperature.

Techniques: Staining

Journal: Gut and Liver

Article Title: High Expression of Ribonucleotide Reductase Subunit M2 Correlates with Poor Prognosis of Hepatocellular Carcinoma

doi: 10.5009/gnl13392

Figure Lengend Snippet: Correlations between Ribonucleotide Reductase Subunit M2 Expression and Clinicopathologic Features in 259 Patients with Hepatocellular Carcinomas

Article Snippet: Sections were incubated with mouse monoclonal antibody to RRM2 (clone 1E1, 1:800; Abcam Corp., Cambridge, MA, USA) for 30 minutes at room temperature.

Techniques: Expressing

Journal: Gut and Liver

Article Title: High Expression of Ribonucleotide Reductase Subunit M2 Correlates with Poor Prognosis of Hepatocellular Carcinoma

doi: 10.5009/gnl13392

Figure Lengend Snippet: Univariate and Multivariate Logistic Regression Models for Predicting Early Tumor Recurrence in 259 Patients with Hepatocellular Carcinomas

Article Snippet: Sections were incubated with mouse monoclonal antibody to RRM2 (clone 1E1, 1:800; Abcam Corp., Cambridge, MA, USA) for 30 minutes at room temperature.

Techniques: Expressing

Journal: Gut and Liver

Article Title: High Expression of Ribonucleotide Reductase Subunit M2 Correlates with Poor Prognosis of Hepatocellular Carcinoma

doi: 10.5009/gnl13392

Figure Lengend Snippet: Univariate Analyses of Recurrence-Free Survival and Disease-Specific Survival in 259 Patients with Hepatocellular Carcinomas

Article Snippet: Sections were incubated with mouse monoclonal antibody to RRM2 (clone 1E1, 1:800; Abcam Corp., Cambridge, MA, USA) for 30 minutes at room temperature.

Techniques: Expressing

Journal: Gut and Liver

Article Title: High Expression of Ribonucleotide Reductase Subunit M2 Correlates with Poor Prognosis of Hepatocellular Carcinoma

doi: 10.5009/gnl13392

Figure Lengend Snippet: Kaplan-Meier survival curves showing recurrence-free survival (A) and disease-specific survival (B) according to ribonucleotide reductase subunit M2 expression in 259 patients with hepatocellular carcinomas.

Article Snippet: Sections were incubated with mouse monoclonal antibody to RRM2 (clone 1E1, 1:800; Abcam Corp., Cambridge, MA, USA) for 30 minutes at room temperature.

Techniques: Expressing

Journal: Gut and Liver

Article Title: High Expression of Ribonucleotide Reductase Subunit M2 Correlates with Poor Prognosis of Hepatocellular Carcinoma

doi: 10.5009/gnl13392

Figure Lengend Snippet: Multivariate Analyses of Recurrence-Free Survival and Disease-Specific Survival in 259 Patients with Hepatocellular Carcinomas

Article Snippet: Sections were incubated with mouse monoclonal antibody to RRM2 (clone 1E1, 1:800; Abcam Corp., Cambridge, MA, USA) for 30 minutes at room temperature.

Techniques: Expressing